HER2-Enriched Subtype and ERBB2 Expression in HER2-Positive Breast Cancer Treated with Dual HER2 Blockade
2019 · JNCI Journal of the National Cancer Institute · 164 citations
https://doi.org/10.1093/jnci/djz042
F
Fara Brasó‐Maristany
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
301
Papers
3.7K
Citations
28
h-index
43
i10-index
Fara Brasó‐Maristany is an academic researcher from Target (United States). The author has contributed to research in topics: HER2/EGFR in Cancer Research & Advanced Breast Cancer Therapies & Breast Cancer Treatment Studies. The author has an h-index of 28, co-authored 256 publications.
ORCID: 0000-0001-5440-9643Papers by this author
worksCorrelative Biomarker Analysis of Intrinsic Subtypes and Efficacy Across the MONALEESA Phase III Studies
2021 · Journal of Clinical Oncology · 149 citations
https://doi.org/10.1200/jco.20.02977
Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancer
2022 · EBioMedicine · 136 citations
https://doi.org/10.1016/j.ebiom.2021.103801
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
2020 · Nature Communications · 117 citations
https://doi.org/10.1038/s41467-019-14111-3
A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer: a retrospective study with an external evaluation
2020 · The Lancet Oncology · 72 citations
https://doi.org/10.1016/s1470-2045(20)30450-2
Prognostic and Predictive Value of Immune-Related Gene Expression Signatures vs Tumor-Infiltrating Lymphocytes in Early-Stage ERBB2/HER2-Positive Breast Cancer
2023 · JAMA Oncology · 70 citations
https://doi.org/10.1001/jamaoncol.2022.6288
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat